# A Study to Test How Well Different Doses of BI 1831169 in Combination With an Anti-PD1 Antibody Are Tolerated in Japanese People With Different Advanced Cancers

> clinical trial · VERIFIED · 2026-07-07

Status: SUSPENDED · Sponsor: Boehringer Ingelheim · Condition: Solid Tumors

- Company: Boehringer Ingelheim
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT07176975

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.